BridgeBio Pharma (BBIO) Peer Comparison
$63.23
As on 13-Oct-2026 14:39EDT
Market cap
$12,775 Mln
Revenue (TTM)
$713 Mln
P/E Ratio
--
P/B Ratio
123.7
Div. Yield
0 %
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12,775 | 13,100 | 10,594 | 11,447 | 10,162 |
Revenue ($ Mln) |
713 | 831 | 432 | 5,020 | 332,834 |
Net Profit ($ Mln) |
-696.24 | 54.90 | -136.72 | -199.00 | 33,166.55 |
Net Margin (%) |
-97.64 | 6.61 | -31.66 | -3.96 | 9.96 |
RoE (%) |
-- | 8.11 | -30.32 | -3.03 | 8.88 |
Price to Earnings |
-- | 263.46 | -- | -- | 27.73 |
Price-To-Book |
123.68 | 18.00 | 23.58 | 1.71 | 2.58 |
Income Statement ($ Mln)
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
713.07 | 830.81 | 431.80 | 5,020.00 | 332,834.17 |
|
Cost of Revenue
|
47.45 | 14.09 | 207.41 | 2,380.00 | 165,910.29 |
|
Gross Profit
|
473.81 | 748.43 | 191.00 | 2,050.00 | 190,428.00 |
|
Operating Expenses
|
1,209.09 | 810.32 | 362.16 | 2,178.00 | 131,728.10 |
|
Operating Profit (EBIT)
|
-543.47 | 6.41 | -137.77 | 462.00 | 35,195.77 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-706.17 | 26.37 | -135.85 | -166.00 | 41,359.76 |
|
Provision for Tax
|
-7.73 | -35.26 | 0.24 | 33.00 | 8,582.66 |
|
Profit after Tax (Net Income)
|
-696.24 | 54.90 | -136.72 | -199.00 | 33,166.55 |
|
Minority Interest
|
10.15 | 0.00 | 0.00 | 0.00 | 389.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 25,570.00 |
Liabilities ($ Mln)
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-2,515.22 | 705.78 | 445.74 | 6,588.00 | 383,428.00 |
|
Minority Interest
|
10.15 | 0.00 | 0.00 | 0.00 | 389.00 |
|
Non-Current Liabilities
|
2,832.54 | 29.12 | 106.44 | 5,121.00 | 31,229.00 |
|
Current Liabilities
|
890.65 | 153.80 | 120.26 | 1,852.00 | 157,341.00 |
|
Total Liabilities
|
936.03 | 836.65 | 641.86 | 13,358.00 | 492,989.00 |
Assets ($ Mln)
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
124.16 | 449.03 | 351.14 | 9,764.00 | 275,974.00 |
|
Current Assets
|
1,093.14 | 439.68 | 321.30 | 3,797.00 | 299,331.00 |
|
Total Assets
|
936.03 | 836.65 | 641.86 | 13,358.00 | 492,989.00 |
|
Total Debt*
|
2,493.78 | 9.42 | 93.59 | 3,918.00 | 71,952.00 |
|
Net Current Assets
|
202.49 | 285.87 | 201.04 | 1,945.00 | 141,990.00 |
Cashflow ($ Mln)
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-445.91 | 142.00 | -47.63 | 560.00 | 46,428.00 |
|
Cash Flow from Investing Activities
|
-24.49 | 69.76 | -24.76 | -279.00 | -58,077.00 |
|
Cash from Financing Activities
|
359.29 | -220.37 | 28.54 | -275.00 | 18,911.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-159.44 | 14.87 | -13.30 | -2.21 | 16.61 |
|
ROE (%)
|
41.15 | 8.11 | -30.32 | -3.03 | 8.88 |
|
ROA (%)
|
-41.39 | 5.52 | -17.95 | -1.30 | 4.76 |
|
EBIT Margin (%)
|
-86.43 | 3.17 | -30.84 | 1.61 | 11.97 |
|
Net Margin (%)
|
-97.64 | 6.61 | -31.66 | -3.96 | 9.96 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
202.39 | 16.02 | 19.19 | 11.95 | -0.43 |
|
EBIT Growth (%)
|
5.05 | -79.11 | -57.38 | -90.61 | -50.25 |
|
Net Profit Growth (%)
|
10.33 | -58.66 | -60.49 | -145.85 | -41.61 |
|
EPS Growth (%)
|
12.58 | -62.44 | -52.59 | -146.42 | -41.56 |
|
Book Value Growth (%)
|
-36.90 | 12.98 | -8.64 | -3.87 | 9.58 |
Valuation Ratios
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-20.69 | 41.86 | -21.89 | -48.47 | 0.19 |
|
Price / Book Value
|
-7.27 | 6.44 | 3.60 | 1.72 | 0.03 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-25.47 | 55.67 | -30.81 | 21.77 | 0.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-0.77 | 0.00 | 0.00 | 0.58 | 0.00 |
|
Short term debt to equity ratio
|
-0.22 | 0.00 | 0.02 | 0.01 | 0.16 |
|
Current Ratio
|
1.23 | 2.86 | 2.67 | 2.05 | 1.90 |
|
Quick Ratio
|
1.17 | 2.77 | 2.38 | 1.10 | 1.39 |
|
Interest Coverage
|
-6.86 | -- | -- | 0.36 | 10.86 |
Operating Efficiency Ratios
| BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
35.69 | 9.26 | 15.23 | 22.95 | 37.38 |
|
Asset Turnover
|
0.42 | 0.84 | 0.57 | 0.33 | 0.48 |
|
Receivable days
|
52.44 | 28.27 | 44.72 | 70.73 | 115.08 |
|
Inventory Days
|
172.81 | 355.76 | 51.56 | 226.89 | 181.99 |
|
Payable days
|
296.14 | 785.55 | 12.52 | 45.50 | 56.23 |
|
Cash Conversion Cycle
|
-70.89 | -401.52 | 83.76 | 252.12 | 240.84 |